World Generic Medicines Congress 2016
Start:
Wed, 10 Feb 2016, 08:00
End:
Thu, 11 Feb 2016, 17:00
Venue:
Exhibit
Symposia
Workshops
Organiser
Sponsor
Your opportunity
Why sponsor
Who will you meet
10 Reasons to Attend
- Identify where the generics industry growth opportunities are
- Gain an investor’s perspective on the generics market and
understand what this means for your business
- Hear the latest legal and regulatory developments that will shape
your strategy decisions
- Explore the growth opportunities of complex generics to
strengthen business models
- Understand the current market trends and future challenges for
biosimilar success
- Learn the impact of the current EU & US health policy
environment on generic medicines
- Interact, debate and discuss the key topics of the generics and
biosimilar industry at peer-to-peer roundtable discussions
- Discover untapped opportunities in the global market
- Collocated with create your own agenda and
attend focussed sessions most relevant to your business needs
- Network with pioneers, influencers and innovators and return to
your company with new ideas and relationships
.
.
Booking code | BR03 | |
Package | Before 22nd January 2016 | Full price |
2 Day conference | £1,495 | £1,595 |
To Register Click Here
World Generic Medicines Congress day 1 | |
08:00 | Registration |
Generics and Biosimilars Commercial Strategy | |
08:50 | Opening remarks from the chair |
09:00 | Generics market focus |
Tommy Erdei, Global Joint Head of Pharmaceuticals and Life Sciences, Joint Head of European Healthcare Investment Banking,, Jefferies Group | |
09:30 | Successful strategies to build new business, open up new markets and grow market share in MENA |
Mazen S Darwazeh, Vice Chairman President & CEO MENA & Emerging Markets, Hikma Pharmaceuticals | |
10:00 | The future of the biosimilar industry - mapping the evolution and development of the biosimilar sector |
Mr Sandeep Athalye, Vice President and Head CDMA, Biosimilars, Boehringer Ingelheim | |
Mr Bruce Lott, Vice President of State Government Relations, Mylan Inc. | |
Dr Cyrus Karkaria, President - Biotechnology, Lupin Pharma | |
10:45 | Speed networking |
11:00 | Morning refreshments |
11:30 | Biosimilars - A View From The Capital Markets |
Mr Ashwin Pai, Senior Vice President Healthcare Investment Banking, Jefferies International | |
12:00 | Government affairs affecting the US generics and Biosimilar market |
Mr Bruce Lott, Vice President of State Government Relations, Mylan Inc. | |
12:30 | Lunch |
13:30 | PEER TO PEER ROUNDTABLES |
| |
| |
| |
| |
| |
| |
Generics | |
Afternoon Chair: Nitin Naik, Vice President-Global Life Sciences, Frost and Sullivan | |
15:00 | Topic TBC |
15:30 | Afternoon refreshments |
16:00 | Role of R&D and niche area expertise |
Dr Deepak Murpani, Global R&D Head, Polpharma | |
16:30 | How smaller generic companies are competing in challenging EU countries |
Ullrich Hanstein, General Manager, Help S.A. | |
17:00 | Closing remarks from the chair |
17:05 | Drinks party |
World Generic Medicines Congress day 2 | |
08:00 | Registration |
08:50 | Opening remarks from the chair |
Mr Simon Cohen, Partner, Taylor Wessing | |
Generic Market Analysis | |
09:00 | Current themes dominating US Generics |
Ms Apurva Saraf, Vice President - Global Strategy and Corporate Development, Amneal | |
09:30 | Value of Generic Medicines |
Dr Pieter Dylst, Health Economics Officer, E.G.A. European Generic Medicines Association | |
10:00 | The frenzy of M&A in Generics |
Claudio Albrecht, Former CEO and Chairman of the Board of Directors, Actavis Group, Founder and Managing Partner, Albrecht, Prock & Partners AG | |
10:30 | Strategic Marketing: Emerging versus mature markets |
Mr Sameer Agarwal, Senior Vice President-Portfolio & Marketing, Mature & Emerging Markets, Frenesius Kabi | |
11:00 | Morning refreshments |
Payer Power | |
11:30 | Purchasing power: how to influence purchasing decisions |
Evert Jan van Lente, Director of EU Affairs, AOK Bundesverdand | |
12:00 | An Industry Observer's Perspective on Cost Containment and Procurement of Generics |
Mr Peter Wittner, Senior Consultant, Interpharm Consultancy | |
12:30 | PANEL DISCUSSION: Trends in pricing and profits |
Frances Cloud, Founder, Pharmacloud Ltd | |
Evert Jan van Lente, Director of EU Affairs, AOK Bundesverdand | |
Mr Peter Wittner, Senior Consultant, Interpharm Consultancy | |
13:30 | Lunch |
14:30 | Legal and IP strategies for the generic medicines |
Saufung Ma, Senior Associate, Taylor Wessing | |
Mr Simon Cohen, Partner, Taylor Wessing | |
15:00 | Advantages of Trade Policy to the generic and biosimilar industry |
Mr David Jauch, Global Regulatory Affairs and Government Relations Manager, Fresenius Kabi | |
15:30 | Afternoon refreshments |
16:00 | Updates on health policies |
Juliana Reed, Vice President, Government Affairs, Hospira | |
16:30 | Generics product development from a CDMO perspective |
Reserved for GB Patent | |
Mr Antonio Lopez, Director of Business Management for Spain, Portugal and France, Recipharm | |
Amine Tahiri, Sales Director South EU, Development & technology, Recipharm | |
17:00 | Closing remarks from the chair |
More events
Thu, 18 Jul 2024 - Sun, 21 Jul 2024
Fri, 19 Jul 2024 - Sat, 20 Jul 2024
Sun, 21 Jul 2024 - Tue, 23 Jul 2024
Mon, 22 Jul 2024 - Fri, 26 Jul 2024
Sat, 27 Jul 2024 - Fri, 28 Jun 2024
Sun, 28 Jul 2024 - Thu, 1 Aug 2024
Thu, 1 Aug 2024 - Sat, 3 Aug 2024
Thu, 1 Aug 2024 - Sun, 4 Aug 2024